Catalog No.
AHB87801
Biological activity
Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVENval-WRK(Dnp)-NH2. The specific activity is >30 pmol/min/μg, as measured under the described conditions.
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Thr29-Thr461
Nature
Recombinant
Endotoxin level
<0.1 EU/μg of the protein by the LAL method.
Purity
>90% as determined by SDS-PAGE.
Accession
P00740
Applications
Bioactivity, ELISA, Immunogen, SDS-PAGE, WB
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Plasma thromboplastin component, F9, Christmas factor, Coagulation factor IX, PTC
Multiplex and multimodal mapping of variant effects in secreted proteins via MultiSTEP., PMID:40514537
Hemophilia is associated with accelerated biological aging., PMID:40079104
Use of Oral Anti-Xa Inhibitor in Prosthetic Mechanical Aortic Valve with Warfarin Hypersensitivity Due to the FIX p.(Ala37Thr) Propeptide Variant: Case Report and Literature Review., PMID:40015335
Multiplex, multimodal mapping of variant effects in secreted proteins., PMID:39975210
CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy., PMID:39768347
Hemophilia B Leyden: characteristics and natural history in the International Pediatric Network of Hemophilia Management Registry., PMID:39742973
Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia B: a case report., PMID:39609856
TRIM28 regulates the coagulation cascade inhibited by p72 of African swine fever virus., PMID:39533356
A de novo int22h-1/int22h-2-flanked Xq28 deletion-associated preferential X-inactivation in a female with severe hemophilia B., PMID:39289866
The genetic analysis of eight families with hemophilia B in Mongolia: Identification of two novel mutation., PMID:39268837
Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China., PMID:39260745
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives., PMID:39062568
Human umbilical cord mesenchymal stem cell-based gene therapy for hemophilia B using scAAV-DJ/8-LP1-hFIXco transduction., PMID:39020429
An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B., PMID:39019441
Genotype-phenotype analyses of Iranian patients with hemophilia B (Leyden -) and hemophilia B (Leyden +): A single-center study., PMID:38964254
Proteomic characteristics of the aqueous humor in Uyghur patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma., PMID:38642601
Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study., PMID:38561593
Genetic variant detection in a South African haemophilia B population., PMID:38462783
Multiple venous thrombosis caused by F9 gene duplication and treated with catheter-directed thrombolysis, AngioJet-assisted pharmaco-mechanical thromboectomy and manual aspiration thromboectomy., PMID:38358900
Pleiotropic effects of different exonic nucleotide changes at the same position contribute to hemophilia B phenotypic variation., PMID:38184202
Complete F9 Gene Deletion, Duplication, and Triplication Rearrangements: Implications for Factor IX Expression and Clinical Phenotypes., PMID:38011862
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)., PMID:37962325
Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients., PMID:37722393
Gene Therapy Approaches for the Treatment of Hemophilia B., PMID:37445943
A unique case of thrombophilia: the role of F9 gene duplication and increased factor IX activity in cerebral venous thrombosis., PMID:37414287
The EGF Motif With CXDXXXXYXCXC Sequence Suppresses Fibrosis in a Mouse Skin Wound Model., PMID:37369508
Structural and functional exploration of three newly identified coagulation factor IX mutations in Chinese hemophilia B patients., PMID:37210691
Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B., PMID:36795372
An updated interactive database for 1692 genetic variants in coagulation factor IX provides detailed insights into hemophilia B., PMID:36787808
Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice., PMID:36549291
F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B., PMID:36347023
A Machine Learning Framework Predicts the Clinical Severity of Hemophilia B Caused by Point-Mutations., PMID:36304295
Accessibility and visibility of genetic testing for haemophilia across Europe: Where do we stand?, PMID:36222225
Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China., PMID:36163649
Experimental Bothropsatrox Envenomation: Blood Plasma Proteome Effects after Local Tissue Damage and Perspectives on Thromboinflammation., PMID:36136550
Clinical profile of hemophilia B patients from Karnataka., PMID:36119352
Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology., PMID:35883203
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications., PMID:35842956
Long-term correction of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration., PMID:35691554
Structural, functional, and immunogenicity implications of F9 gene recoding., PMID:35413099
Effects of 14 F9 synonymous codon variants on hemophilia B expression: Alteration of splicing along with protein expression., PMID:35391506
F9 mRNA splicing aberration due to a deep Intronic structural variation in a patient with moderate hemophilia B., PMID:35313235
The Molecular Basis of FIX Deficiency in Hemophilia B., PMID:35269902
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence., PMID:35184131
Generation an induced pluripotent stem cell line SXMUi001-A derived from a hemophilia B patient carries variant F9 c.223C＞T(p.R75X)., PMID:35121195
Alu element in the RNA binding motif protein, X-linked 2 (RBMX2) gene found to be linked to bipolar disorder., PMID:34914762
Hemophilia gene therapy: ushering in a new treatment paradigm?, PMID:34889378
Genetic and Bioinformatic Strategies to Improve Diagnosis in Three Inherited Bleeding Disorders in Bogotá, Colombia., PMID:34828413
A Single Base Insertion in F9 Causing Hemophilia B in a Family of Newfoundland-Parti Standard Poodle Hybrid Dogs., PMID:34680886
Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion., PMID:34649996
For research use only. Not for human or drug use.
